Overview

• Diabetes technology firm's Q4 worldwide sales rose 3%, with international sales up 17%

• Company began rollout of t:slim X2 pump integration with FreeStyle Libre 3 Plus sensor

Outlook

• Company projects 2026 full-year sales of $1.065 bln to $1.085 bln

• Tandem Diabetes expects 2026 gross margin of 56% to 57%

• Company anticipates 2026 adjusted EBITDA margin of 5% to 6%

Result Drivers

• INTERNATIONAL SALES GROWTH - International sales increased 17% to $79.9 mln, driven by pump shipments and strategic expansion

• PRODUCT INTEGRATION - Global rollout of t:slim X2 pump with FreeStyle Libre 3 Plus sensor contributed to sales

• GROSS MARGIN IMPROVEMENT - Record quarterly gross margin of 58% achieved, attributed to operational improvements

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Tandem Diabetes Care Inc is $22.50, about 18.8% above its February 18 closing price of $18.94

Press Release: ID:nBw4CyTJLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)